2020
Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events
Herrmann SM, Perazella MA. Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events. Kidney International Reports 2020, 5: 1139-1148. PMID: 32775813, PMCID: PMC7403510, DOI: 10.1016/j.ekir.2020.04.018.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsAcute kidney injuryCheckpoint inhibitorsAdverse renal effectsAdverse renal eventsSubset of patientsPotential risk factorsAcute rejectionRenal eventsKidney injuryRenal effectsTransplant populationRenal toxicityRisk factorsBetter outcomesPatientsNephrotoxicityCliniciansCancer therapyCancerRecent studiesInhibitorsCurrent informationComplicationsProviders
2001
COX-2 Inhibitors and the Kidney
Perazella M. COX-2 Inhibitors and the Kidney. Hospital Practice 2001, 36: 43-56. PMID: 11263799, DOI: 10.3810/hp.2001.03.230.Peer-Reviewed Original Research
2000
Are selective COX-2 inhibitors nephrotoxic?
Perazella M, Eras J. Are selective COX-2 inhibitors nephrotoxic? American Journal Of Kidney Diseases 2000, 35: 937-940. PMID: 10793030, DOI: 10.1016/s0272-6386(00)70266-6.Peer-Reviewed Original ResearchConceptsHigh-risk patientsRenal insufficiencySelective cyclooxygenase-2 enzyme inhibitorsSuch high-risk patientsNonsteroidal anti-inflammatory drugsSelective COX-2 inhibitorsChronic renal impairmentChronic renal insufficiencyAcute renal failureAcute renal insufficiencyAdverse gastrointestinal effectsCyclooxygenase-2 enzyme inhibitorsAnti-inflammatory drugsCourse of therapyCOX-2 inhibitorsPain syndromeRenal impairmentRenal failureGastrointestinal effectsNephrotoxic potentialInflammatory diseasesEnzyme inhibitorsPatientsInsufficiencyInhibitors